Ascending the SUMMIT: Tirzepatide’s Breakthrough in HFpEF
Aug 08, 2025•18 min
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
Heart failure with preserved ejection fraction (HFpEF) poses a significant challenge because of its heterogeneous nature and the scarcity of therapies that meaningfully alter its course. The SUMMIT study evaluated the impact of tirzepatide on symptoms and mortality in people with HFpEF and obesity.
Guests: Jennifer N. Clements, Pharm.D., FCCP, FADCES, BCPS, BCACP, BC-ADM, CDCES and Dawn C. Fuke, Pharm.D., BCPS, BCACP
Music by Good Talk
For the best experience, listen in Metacast app for iOS or Android